Comparative Pharmacology
Head-to-head clinical analysis: FLUCONAZOLE IN DEXTROSE 5 IN PLASTIC CONTAINER versus MYCELEX 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUCONAZOLE IN DEXTROSE 5 IN PLASTIC CONTAINER versus MYCELEX 7.
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER vs MYCELEX-7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluconazole selectively inhibits fungal cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and inhibition of fungal growth.
Clotrimazole, an azole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
200-400 mg IV once daily; for candidemia or invasive candidiasis, loading dose of 800 mg IV on day 1, then 400 mg IV once daily.
Clotrimazole 100 mg vaginal tablet inserted intravaginally once daily at bedtime for 7 days.
None Documented
None Documented
Terminal elimination half-life approximately 30 hours (range 20-50 hours). Prolonged in renal impairment (up to 98 hours in CrCl <20 mL/min).
The systemic half-life of clotrimazole following vaginal administration is approximately 0.5–1 hour due to rapid metabolism and elimination. This short half-life reflects minimal systemic absorption (3–10%).
Renal: 80% unchanged drug; feces: 11%; biliary: minor.
Primarily via feces as unchanged drug (approx. 50%) and metabolites. Renal excretion of unchanged drug is minimal (<1%) as the drug is poorly absorbed from the vagina. Biliary excretion contributes to fecal elimination.
Category A/B
Category C
Azole Antifungal
Azole Antifungal